ALKSAlkermes plc.
Alkermes plc. (ALKS) sells proprietary drugs and acquired assets like LUMRYZ (sodium oxybate), targeting rare sleep disorders and neurological conditions. The next catalyst is Sep 23, 2026 — Alkermes Falls as Investors Appear to Take Profits Despite No Obvious Negative…, which will test investor sentiment ahead of key regulatory and clinical events.
- Revenue fell 5.2% YoY to $1.67B, with net loss of $49.7M and free cash flow of $333.5M.
- Leverage is low at 0.16x debt-to-equity, but net margins remain negative at -3.0%.
- Free cash flow is a key strength, though revenue growth is slowing.
The schedule
- Sun13Dec
ALKS 2680 Regulatory & Clinical Strategy Update
- Tue12Jan
LUMRYZ sNDA PDUFA Date (Idiopathic Hypersomnia)
- Fri4Jun
Alkermes (NASDAQ: ALKS) officer readies stock sale
Past
- Wed23Sep
Alkermes Falls as Investors Appear to Take Profits Despite No Obvious Negative…
- Wed29Jul
Actual outcome: Mixed · $48.99 at outcome
Alkermes reported Q2 earnings that met expectations alongside a revenue beat, driven by growth in its proprietary product portfolio and the first full-quarter contribution from LUMRYZ. The company also maintained its full-year 2026 revenue guidance and highlighted progress in its orexin pipeline. Despite these positive operational updates, the stock saw a muted reaction, rising just 1.3% as the results failed to provide a strong enough catalyst to drive a significant directional move.
Alkermes reported Q2 earnings that met expectations alongside a revenue beat, driven by growth in its proprietary product portfolio and the first full-quarter contribution from LUMRYZ. The company also maintained its full-year 2026 revenue guidance and highlighted progress in its orexin pipeline. Despite these positive operational updates, the stock saw a muted reaction, rising just 1.3% as the results failed to provide a strong enough catalyst to drive a significant directional move.
- Tue28Jul
Actual outcome: Mixed · $48.99 at outcome
Alkermes reported Q2 earnings that met EPS estimates and beat revenue expectations, driven by strong proprietary product sales and momentum from its Lumryz acquisition. However, while the company highlighted general progress in its orexin development pipeline, the lack of a definitive Phase 2 data readout for ALKS 2680 left investors without a clear catalyst, resulting in a muted 3% decline in the stock.
Alkermes reported Q2 earnings that met EPS estimates and beat revenue expectations, driven by strong proprietary product sales and momentum from its Lumryz acquisition. However, while the company highlighted general progress in its orexin development pipeline, the lack of a definitive Phase 2 data readout for ALKS 2680 left investors without a clear catalyst, resulting in a muted 3% decline in the stock.
- Tue28Jul
Actual outcome: Bear · $48.99 at outcome
Alkermes reported break-even Q2 earnings and topped revenue estimates, driven by strong proprietary product sales and the first full-quarter contribution from LUMRYZ. Despite the top- and bottom-line beats and reiterated full-year revenue guidance, the stock declined and fell well below the $58 bear floor, indicating that market concerns overshadowed the quarterly results and the LUMRYZ sNDA submission progress.
Alkermes reported break-even Q2 earnings and topped revenue estimates, driven by strong proprietary product sales and the first full-quarter contribution from LUMRYZ. Despite the top- and bottom-line beats and reiterated full-year revenue guidance, the stock declined and fell well below the $58 bear floor, indicating that market concerns overshadowed the quarterly results and the LUMRYZ sNDA submission progress.
- Tue5May
Actual outcome: Bull · $35.47 at outcome
Alkermes reported upbeat Q1 2026 results, beating revenue estimates driven by a 28% increase in proprietary drug sales and a strong $39.5 million contribution from the newly acquired LUMRYZ. The stock held above the bull target as analysts raised their forecasts based on the strong top-line growth and improved adjusted EBITDA. Shortly after the earnings release, positive Phase 3 trial results for LUMRYZ in idiopathic hypersomnia provided an additional major catalyst, driving the stock significantly higher in the following weeks.
Alkermes reported upbeat Q1 2026 results, beating revenue estimates driven by a 28% increase in proprietary drug sales and a strong $39.5 million contribution from the newly acquired LUMRYZ. The stock held above the bull target as analysts raised their forecasts based on the strong top-line growth and improved adjusted EBITDA. Shortly after the earnings release, positive Phase 3 trial results for LUMRYZ in idiopathic hypersomnia provided an additional major catalyst, driving the stock significantly higher in the following weeks.
- Thu5Mar
Actual outcome: Bull · $33.22 at outcome
Alkermes exceeded its bull target, rising 17.2% following a strong Q4 earnings and revenue beat. Management outlined a robust 2026 strategic plan focused on expanding its commercial platform post-Avadel acquisition and advancing its late-stage orexin pipeline, alongside a clear CEO succession plan. These positive fundamental developments and pipeline advancements drove sustained upward momentum in the stock.
Alkermes exceeded its bull target, rising 17.2% following a strong Q4 earnings and revenue beat. Management outlined a robust 2026 strategic plan focused on expanding its commercial platform post-Avadel acquisition and advancing its late-stage orexin pipeline, alongside a clear CEO succession plan. These positive fundamental developments and pipeline advancements drove sustained upward momentum in the stock.
- Wed11Feb
Actual outcome: Bear · $32.02 at outcome
Alkermes reported Q4 2025 earnings that exactly met consensus estimates with an EPS of $0.30. However, the stock fell 8.3% to hit the bear floor as the accompanying 2026 forward guidance failed to meet market expectations. The lack of an earnings beat combined with a softer outlook for the upcoming year drove the material sell-off.
Alkermes reported Q4 2025 earnings that exactly met consensus estimates with an EPS of $0.30. However, the stock fell 8.3% to hit the bear floor as the accompanying 2026 forward guidance failed to meet market expectations. The lack of an earnings beat combined with a softer outlook for the upcoming year drove the material sell-off.
